Clinical research is advancing for the future treatment of advanced cancers. A new report has disclosed the results of a phase III clinical study in which renal Cancer patients were treated with two drugs: one used in immunotherapy, and one targeted to renal cancer.

The results show that the tumor shrunk in more than 55% of the patients versus 25% of the patients that received standard treatment with the targeted drug only.

However, many (38%) patients suffered from side effects related to the activation of the immune system, mostly resulting in thyroid disorders. The combined treatment is not curative, but prolongs life.

Read the full story: Dana-Farber Cancer Institute
Scientific publication: New England Journal of Medicine